SEC Comment Letter 0000000000-24-003220 to LEAP THERAPEUTICS, INC. (LPTX) (CIK 0001509745) (CYPH)
LEAP THERAPEUTICS, INC. (LPTX) (CIK 0001509745)
Date: March 25, 2024 · CIK: 0001509745 · Accession: 0000000000-24-003220
AI Filing Summary & Sentiment
File numbers found in text: 333-278015
Letter
United States securities and exchange commission logo March 25, 2024 Douglas Onsi Chief Executive Officer Leap Therapeutics, Inc. 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 Re:Leap Therapeutics, Inc. Registration Statement on Form S-3 Filed March 18, 2024 File No. 333-278015 Dear Douglas Onsi: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Julio E. Vega, Esq.
Show Raw Text
United States securities and exchange commission logo
March 25, 2024
Douglas Onsi
Chief Executive Officer
Leap Therapeutics, Inc.
47 Thorndike Street, Suite B1-1
Cambridge, MA 02141
Re:Leap Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 18, 2024
File No. 333-278015
Dear Douglas Onsi:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Julio E. Vega, Esq.